0.60
+5.90%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Invivyd
From its filings with the US Securities and Exchange Commission
Invivyd is based in New Haven, Connecticut and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker IVVD. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $53.4m and a net loss of $52.5m. At that date it held total assets of $276.9m and shareholders' equity of $241.5m.
Invivyd, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of monoclonal antibody (“mAb”) therapies for the prevention and treatment of serious viral infectious diseases. We are devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2, the virus that causes COVID-19. PEMGARDA® (pemivibart) is our first mAb to receive regulatory authorization and was designed to exert continuous pharmaceutical activity in the face of viral evolution.
Globally, COVID-19 has caused millions of deaths and lasting health problems in many survivors and remains a significant global health concern, particularly for immunocompromised individuals. COVID-19 persists and continues to impact patients, notably those who are immunocompromised, and combating this disease will require for years to come a variety of prevention and treatment options with demonstrated efficacy and safety. By leveraging our capabilities, which we have developed through our experience with adintrevimab and pemivibart and over five years in the COVID-19 space, we aim to develop mAbs that could be used in prevention or treatment of serious viral infectious diseases, starting with COVID-19 and expanding into other high-need indications, such as respiratory syncytial virus (“RSV”) and measles.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 6 Aug 2021
- Employees
- 122
- Website
- invivyd.com ↗
- Head office
- 205 CHURCH STREET, NEW HAVEN, CT
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Marc EliaIndependent Chairman of the Board, since 2022$150,770
- Mr. William DukePrincipal Executive Officer, Chief Financial Officer$635,543
- Ms. Julie GreenChief Human Resources Officer, Head of Communications$1.6m
- Mr. Robert AllenChief Scientific Officer$2.0m
- Ms. Kristie KuhlChief Communications Officer
- Mr. Timothy LeeChief Commercial Officer$1.0m
- Ms. Jill AndersenCorporate Secretary, Chief Legal Officer$2.1m
- Dr. Paul BolnoDirector
- Ms. Tamsin BerryIndependent Director$109,865
- Ms. Christine LindenboomIndependent Director$157,603
- Mr. Terrance McguireIndependent Director$109,270
- Mr. Kevin MclaughlinIndependent Director$167,325
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 24
- Environment
- 22
- Social
- 14
- Governance
- 37
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Waltham, Massachusetts with a focus on biotechnology within the health care sector.
- IPO occurred on 2021-08-06, indicating market entry and potential for growth.
- Developing antibody-based solutions for infectious diseases with pandemic potential.
Weaknesses
- Employee count listed as 122 in company data but 84 in source description, indicating inconsistency.
- Source description treats facts as untrusted, suggesting potential inaccuracies in provided data.
- Limited information on current commercialization status beyond pipeline candidates.
Opportunities
- Growing demand for antibody-based therapies addressing viral threats like SARS-CoV-2.
- Pipeline includes VYD222, a monoclonal antibody candidate with demonstrated neutralizing activity.
- Technology intersects evolutionary virology, predictive modeling, and antibody engineering.
Threats
- Untrusted source description may lead to unreliable data for stakeholders.
- Dependence on pipeline candidates like VYD222 for commercial success.
- Potential market competition in antibody-based therapies for infectious diseases.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.